Sign in

New Light-Drug Combo Developed for Skin Cancer Treatment

A drug that is activated by light can be a quick, simple, and cheap treatment for tens of thousands of patients with skin cancer in Sweden. Researcher Leif Eriksson’s team at Örebro University in Sweden has now received about SEK 4 million from government research financiers, the Swedish Research Council and Vinnova to further develop and commercialize the method.

The new drug that the Örebro researchers have developed is based on the use of photodynamic therapy in cancer treatment. In short, this is a drug that, after reorganization in the cell, is activated by light, which in turn leads to chemical reactions that effectively kills cancer cells.

With this method, a majority of the some 30,000 new cases of skin cancer discovered each year in Sweden alone could be treated quickly, simply and cost effectively. This is also true for pre-stages of skin cancer, so-called actinic keratosis.

“It’s extremely gratifying that two of the most important research financiers in Sweden so actively support our research,” says Eriksson, professor of biophysical and theoretical chemistry at Örebro University. Eriksson’s drug research has grown out of the Örebro Life Science Center (OLSC), an interdisciplinary, internationally acclaimed research node at Örebro University.

Research on new forms of treatment for skin tumors is also being conducted in collaboration with associate professor Lennart Löfgren at the Center for Head and Neck Oncology at Örebro University Hospital. “Our drug, and the new treatment concept we are developing together with researchers in Belfast has tremendous potential. In the coming year, we will also see further patents as a direct result of the collaboration with other research teams within the OLSC, including treatments for atherosclerosis and autoimmune disorders such as rheumatism,” says Eriksson.

The development of new drugs is being carried out with the aid of advanced computer modeling—a method that has proven to be highly successful. “We provide the expertise in the theoretical description of new drugs. In our research, we aim to describe at a detailed level what they should look like, what properties they should have to match the right targets in the body, what happens if we alter the molecules in different ways, and so on. We then put this together through collaboration with experimental or clinically active research teams within OLSC and at the hospital, which makes the research exciting and dynamic,” says Eriksson.

Adapted from materials provided by Vetenskapsrådet (The Swedish Research Council), via AlphaGalileo.

ScienceDaily, December 7, 2008

Related Content